Canadian Institutes for Health Research (CIHR), Canada

2015

  • Acceleration of Tooth Movement in Bisphosphonate Burdened Alveolar Bone
  • Canada Research Chair in Molecular Genetics
  • Canada Research Chair in Molecular Hemostasis
  • Cell size specification in normal and malignant populations
  • Characterizing the role and regulation of the mammalian tumor suppressor gene Fat4 on metabolism, mitochondrial complex activity and stability
  • Common Pathogenic Pathways and Therapeutics for SMA and ALS motoneuron diseases
  • Computation and theory to predict structures and mechanisms for protein misfolding in amyotrophic lateral sclerosis
  • Copy number variations (CNVs) and colorectal cancer
  • Developing evidence for more effective handrail design to prevent falls and inform changes in the Canada Building Code
  • Development of Genomic and Bioinformatic Tools and Methodologies to Identify Potential Drug Targets for Aortic Stenosis Therapeutics
  • Discovery of Novel Therapeutic Targets in Osteosarcoma
  • Elucidation of regulatory mechanisms modulating STAT3 expression during cancer-induced muscle atrophy
  • Exome sequencing of patients with Weaver-like features links another cancer gene, EED, to overgrowth syndromes.
  • Genetics of Obesity
  • Gfi1, a new regulator of the DNA Damage Response Pathway in T lymphocytes and T cell Leukemia
  • Human Cancer Stem Cell Biology
  • Immunotherapy of familial prion diseases
  • Impact of VEPH1 on cancer associated signaling pathways in the promotion of ovarian cancer
  • Innovative chemogenomic tools to improve outcome in acute myeloid leukemia
  • Integrated Genomic and Epigenomic Analysis of Regulatory Elements in Glioblastoma
  • Investigating a tumor suppressor role for Parkinson’s susceptibility gene LRRK2 in lung cancer
  • Investigating the use of Smac mimetic compounds combined with innate immune stimuli to induce rhabdomyosarcoma cell death
  • Investigation of premature-aging like phenotypes in ATRX mutant mice
  • Long QT Syndrome in Northern British Columbia: Predicting Risk for sudden death
  • Modulation of the DNA damage repair (DDR) response in the treatment of brain tumors
  • Molecular and Genomic Pathology
  • Molecular Brake Mechanisms That Regulate Brain Plasticity and Disease
  • Molecular Determinants of the Li-Fraumeni Syndrome
  • Mutations in a long non-coding RNA cause Myoclonus Dystonia
  • Novel Therapies for Cystinosis
  • OSMR Signalling in Glioblastoma Pathogenesis
  • Personalized medicine in the treatment of epilepsy
  • Pharmacological suppression of cerebral cavernous malformations
  • Regenerative Cardiovascular Medicine
  • Repurposing biomolecules for the treatment of epidermolysis bullosa
  • Role of eurkaryotic elongation factor-2 kinase (eEF2K) in Alzheimer’s disease and relevance for novel therapies.
  • Role of oncogenic transcription factors in T-cell acute lymphoblastic leukemia
  • Ryanodine receptor mutations in stress-induced arrhythmia: correlating molecular structure with disease phenotype
  • Skeletal muscle satellite cells are located at a closer proximity to capillaries in healthy young compared with older adults
  • Targeting the tumour cell stress response in high-risk childhood cancers
  • The role of Glypican-6 in Recessive Omodysplasia
  • The role of PCL2/PRC2 in hematopoietic stem cells and leukemia
  • Translational and applied genomics of pediatric malignancy
  • Translational research in pulmonary arterial hypertension
  • Traumatic Brain InjuryCognitive Rehabilitation Neuroscience
  • Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes.
  • Understanding the role of the MNK-eIF4E axis in the response and resistance to BRAF inhibitors.
  • White matter integrity and sleep microarchitecture in aging and traumatic brain injury

2013

  • Adeno-associated virus gene replacement in fragile X syndrome
  • An autologous cell therapy approach to treat Duchenne muscular dystrophy using engineered muscle tissue derived from induced pluripotent stem cells
  • Clinical, molecular and pathophysiological characterization of Pol III-related leukodystrophies
  • Connecting the Cell-Type Specific Chromosome Architecture to Gene Regulation, Development and Diseases
  • Evaluating the Mechanism of Action of Small Molecule Modulators of CFTR
  • Genetic analysis of Williams-Beuren syndrome: linking genes with behaviour and cognition
  • Inherited bone marrow failure syndromes: from genomic discoveries to biology
  • iPS cells to model vascular disease in patients with Williams Beuren syndrome
  • Loss of VAPB Function in Amyotrophic Lateral Sclerosis-8 (ALS8)
  • Regulation of Skeletal Muscle Stem Cell Activity by microRNA and Cytoplasmic mRNP Granules
  • Role of RhoGDIalpha in the pathogenesis of congenital and childhood nephrotic syndrome
  • Synaptic targets for therapeutic protection of motor function in a genetic model of ALS
  • The Peroxisome Biogenesis Disorders: From Bench to Bedside
  • Validation of the human farnesyl pyrophosphate synthase (hFPPS) as a therapeutic target and design of pre-clinical candidates for the treatment of multiple myeloma and neurodegenerative diseases

 

2012

  • A small molecule inhibitor of G protein-coupled Receptor Kinase 6 (GRK6) to treat human Multiple Myeloma and related diseases
  • Biological mechanisms contributing to increased risk of facial clefting
  • Can laminin-111 be used to treat Duchenne Muscular Dystrophy alone or in combination with myoblast transplantation?
  • Choroideremia: expanding our understanding, exploring treatments
  • Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes
  • Correction of the dystrophin gene with Zinc Finger Proteins and TAL effector nuclease
  • Developing a Canadian framework for evaluation and decision-making for expensive drugs for rare diseases through innovation, value, and priority setting
  • Developing Effective Policies for Managing Technologies for Rare Diseases
  • Discovering new genes for tetralogy of Fallot and cardiac development
  • Elucidating the Protective Mechanism of Phospho-N17 Huntingtin in Huntington’s disease
  • Emerging team in rare diseases: achieving the “triple aim” for inborn errors of metabolism
  • Emerging Team to identify and characterize novel and existing Hereditary Spastic Paraplegia (HSP) disease genes
  • Emerging Team: The Scleroderma Patient-centered Intervention Network
  • Enhanced CARE for RARE Genetic Diseases in Canada
  • Enzyme Enhancement Therapy for GM1 gangliosidosis
  • Experimental Therapies to prevent pulmonary hypertension and promote lung vascular growth in congenital diaphragmatic hernia
  • Functional analysis of non-coding RNA/chromatin interactions at imprinted Prader-Willi Syndrome locus
  • Functional Dissection of Small RNA Pathways that Impact Chromatin
  • Genetic Regulation of Myogenesis
  • Growth arrest and osteoporosis in Duchenne muscular dystrophy patients treated with glucocorticoids
  • Identifying novel roles of calcineurin signaling in the control of multiple complementary pathways affecting the dystrophic phenotype
  • Magnetic resonance imaging biomarkers in ALS
  • Misfolding of Cu/Zn superoxide dismutase by pathological FUS and TDP43: relevance to amyotrophic lateral sclerosis
  • Molecular regulation of progenitor cell behaviour in the developing retina
  • Molecular Targeting of Critical Domains of AHI-1 Oncoprotein in Chronic Myeloid Leukemia Stem Cells Resistant to Current Tyrosine Kinase Inhibitor Therapy
  • Mucopolysaccharidosis I Disease:  Tools for Discovery and Design of Chaperone Therapeutics Based on Unique Enzyme Production Systems and the Elucidation of the Structure of alpha-L-Iduronidase
  • New directions for the use of genetic information by Aboriginal communities: Lessons learned from Québec First Nations with specific monogenic diseases
  • New emerging team on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): from models to treatment strategies
  • Novel approaches to modulate key targets in the pathogenesis of Huntington Disease
  • Planning Meeting for Developing a Canadian framework for reimbursement decision-making for expensive drugs for rare diseases
  • Post-transcriptional Regulation of Utrophin in Skeletal Muscle: Implications for New Therapeutic Strategies for Duchenne Muscular Dystrophy
  • Prognostic markers and biology of relapsed Hodgkin lymphoma
  • Regeneration of motor neurons controlling movement and respiration from embryonic stem cells
  • Regulation of motor neuron identity and circuit development
  • Roles of sodium-hydrogen exchangers in the development of hereditary cardiomyopathy
  • Sapropterin for treatment of patients with Phenylketonuria: Identification of subpopulations with substantial clinical benefit
  • SIX family transcription factors in adult muscle regeneration
  • TDP-43-mediated pathogenic pathways in ALS and new experimental therapeutics
  • The CHAPTER Study: Congenital Heart Adolescents Participating in Transition Evaluation Research
  • The FACTs Project: FAbry disease Clinical research and Therapeutics
  • The ICHANGE (International CHildhood Astrocytomas iNtegrated Genomics and Epigenomics) Consortium
  • Towards Therapeutics For Genetic Corneal Dystrophies
  • Understanding the pathophysiology of Rasmussen’s encephalitis

 

2011

  • Abnormal Activation of Thymocytes High-Mobility Group Box Protein (TOX) in Cutaneous T Cell Lymphomas: Pathogenic Significance and Clinical Applications
  • CD123-Targeted Auger Electron Radioimmunotherapy of Acute Myelogenous Leukemia (AML)
  • Cellular lipids in Huntington’s disease
  • Characterization of skeletal muscle inflammation, fibrosis, degeneration and atrophy in response to mycobacterium ulcerans infection
  • CIHR Secondary Analysis of Databases:  Canadian Pediatric Surgery Network (CAPSNet)
  • Detection and simulation of femoroacetabular impingement
  • Development of ganglioside-based therapies for Huntington’s disease
  • Exploring the functions of the Bub1 and BubR1 kinases during mitosis
  • Finding of Rare Disease Genes in Canada (FORGE Canada)
  • Glia-neuron crosstalk in early amyotrophic lateral sclerosis pathogenesis
  • Identification of novel genes causing pulmonary fibrosis
  • Maternal Diabetes and Perinatal Programming: Role of Reactive Oxygen Species
  • Mechanisms that Regulate Peroxisome Turnover and their role in Neurodegenerative Diseases
  • Mitochondrial dysfunction and brain energy metabolism in the pathogenesis of Niemann-Pick Type C disease
  • Muscle rehabilitation of cerebral palsy patients recieving botulinum toxin type-A (Botox) treatments
  • Novel anti-inflammatory treatment for Amyotrophic Lateral Sclerosis
  • Nuclear envelopathy in Amyotrophic Lateral Sclerosis-8 (ALS8)
  • Obstetrical Complications and Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus (SLE)
  • Physiological functions of the cellular prion protein
  • Preclinical assessment of clinic ready agents for the treatment of muscular dystrophy and spinal muscular atrophy
  • Preclinical Assessment of Rho-kinase Inhibitors for Chronic Pulmonary Hypertension
  • Role of calcineurin and its signaling modulators in the dystrophic phenotype
  • Role of endoglin in aberrant TGF-beta signaling in scleroderma
  • Role of Xin, an actin-binding protein, in satellite cells and muscular dystrophies
  • Satellite Stem Cells from Skeletal Muscle for the Treatment of Neuromuscular Disease
  • Strategies for therapy of respiratory muscle failure in muscular dystrophy
  • Studies on the molecular pathogenesis of Amyotrophic Lateral Sclerosis
  • The TAR DNA-Binding Protein (TDP-43) and Amyotrophic Lateral Sclerosis

 

2010

  •  Altered balance of synaptic/extrasynaptic NMDA receptor signaling in Huntington disease
  • Artificial zinc finger transcription factors targeting the utrophin promoter as a potential therapy for Duchenne muscular dystrophy
  • Characterization of a novel function for PABPN1: the product of the oculopharyngeal muscular dystrophy disease gene
  • Development of a novel therapy for treatment of Spinal Muscular Atrophy
  • Ensuring effective newborn screening: The case of cystic fibrosis
  • Genome-wide analysis of bone marrow failure-related genetic alterations in inherited bone marrow failure syndromes
  • Genome-wide exon capture for targeted resequencing in patients with familial amyotropic lateral sclerosis
  • Involvement of planar cell polarity pathway in glomerular disease
  • MicroRNA (miRNA) modulation of NFL mRNA degradation and translational silencing in ALS
  • Molecular basis of memory defects in Drosophila Fragile X mutants
  • Molecular Determinants of Li-Fraumeni Syndrome Associated Cancers
  • Molecular mechanisms of organelle inheritance
  • Motor, multisystemic and social participation assessment in myotonic dystrophy type 1: a 9-year longitudinal study
  • Pathobiology and ribosomal insufficiency in Shwachman-Diamond syndrome
  • Pathogenic mechanisms associated with neurofilament disorganization
  • Promoting protection of functionally intact motor units in amyotrophic lateral sclerosis (ALS)
  • Protein transport into and across cellular membranes
  • Role and signaling mechanism of EAT-2, an adaptor involved in anti-tumor immunity